Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

0.9907 +0.0707 (+7.68%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Femasys Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently... 
From Femasys Inc.
Via GlobeNewswire
News headline image
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting
From Femasys Inc.
Via GlobeNewswire
News headline image
Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our advancements for women’s reproductive health 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Inc. at August 20th Virtual Investor Summit Microcap Event
Via ACCESSWIRE
News headline image
FEMY Stock Earnings: Femasys Misses EPS, Misses Revenue for Q2 2024 ↗
FEMY stock results show that Femasys missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products 
From Femasys Inc.
Via GlobeNewswire
News headline image
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Rises 1%; Accenture Shares Surge After Q3 Results ↗
 
Via Benzinga
News headline image
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
From Femasys Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says ↗
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market. 
Via Benzinga
News headline image
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Lee-Sepsick Discussed Company’s FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
Lee-Sepsick Discussed Atlanta-Based Biomedical Company’s Women’s Reproductive Health Products 
From Femasys Inc.
Via GlobeNewswire
News headline image
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024 ↗
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
Team to Drive Strategic Initiatives, Launching Efforts at 2024 ACOG Meeting 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
From Femasys Inc.
Via GlobeNewswire
News headline image
FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 ↗
FEMY stock results show that Femasys beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET... 
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
From Femasys Inc.
Via GlobeNewswire
News headline image
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
From Femasys Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.